Syncona Ltd, the UK investment group, has reaffirmed its goal of achieving £5 billion in net assets by 2032, but only after significant changes in the structure of its portfolio. With net assets per share down by 5.2% at the half year ended 30 September, the company has embarked on a two-pronged strategy. The first part of the plan is to rebalance the portfolio with an emphasis on companies with assets in clinical and late clinical-stage development.
